NeoGenomics Q1 Adj $(0.02) Beats $(0.05) Estimate, Sales $156.24M Beat $149.89M Estimate
Portfolio Pulse from Benzinga Newsdesk
NeoGenomics (NASDAQ:NEO) reported Q1 adjusted losses of $(0.02) per share, surpassing the $(0.05) estimate, and sales of $156.24M, exceeding the $149.89M estimate. This represents a significant improvement over the previous year's performance.
April 30, 2024 | 11:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeoGenomics reported better-than-expected Q1 earnings and sales, indicating a strong performance and growth over the past year.
NeoGenomics' Q1 earnings report exceeded analyst expectations in both earnings per share and sales, showing a significant improvement from the previous year. This positive performance is likely to instill investor confidence and could lead to a short-term uptick in the stock price, given the beat on both top and bottom lines.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100